期刊文献+

321株铜绿假单胞菌分布及耐药性分析 被引量:1

Analysis of 321 Pseudomonas Aeruginosa Distribution and Their Drug Resistance
下载PDF
导出
摘要 目的:了解医院感染铜绿假单胞菌(PAE)在临床的分布及耐药性,为临床医师合理用药提供依据。方法:回顾性调查我院2005年1月至2007年12月PAE的感染情况对分离的321株PAE药敏结果进行统计分析。结果:321株PAE主要分布在呼吸内科脑外科和消化内科的重症监护病房(ICU),PAE对13种抗菌药物药敏试验结果表明耐药率≥50.0%的抗菌药物有头孢噻肟90%、庆大霉素77.6%、头孢吡肟54.8%;头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、阿米卡星、环丙沙星等抗菌药物尚有较高的敏感率;亚胺培南和美罗培南的耐药率均为15.6%和1 6.2%。结论:PAE是医院感染的主要病原菌之一,临床医师在治疗时应根据药敏结果和抗菌药物的药理学特点合理选用抗菌药物,以提高疗效并减少耐药菌株产生。 Objective: To understand nosocomial infection of Pseudomonas aeruginosa (PAE) in the clinical distribution and drug resistance, for clinicians rational drug provide the basis.Methods: We retrospective survey in our hospital from January 2005 to December 2007 the infection of PAE on the separation of 321 PAE drug susceptibility results analyzed.Results:321 PAE mainly in the Respiratory Medicine Department of Gastroenterology, brain surgery and the intensive care unit (ICU), PAE for 14 antimicrobial agents in the drug susceptibility test results showed that the rate of _〉 50.0% of antimicrobial drugs cefotaxime 90%, gantamicin ADM 77.6%, cefepime 54.8%; cefoperazone / sulbactam, piperacillin / tazobactam, amikacin, ciprofloxacin and other antibiotics are still sensitive to the higher rate; PEI imipenem and meropenem resistance rates were 15.6% and 16.2%.Conclusion: PAE is one of the main pathogens of nosocomial infection, clinicians in the treatment shall be based on antimicrobial susceptibility results and the pharmacological characteristics of a reasonable use of antimicrobial agents to enhance efficacy and reduce drug-resistant strains.
出处 《中国医药导刊》 2011年第4期693-693,697,共2页 Chinese Journal of Medicinal Guide
关键词 铜绿假单胞菌 分布 耐药情况 Pseudomonas aeruginosa Distribution Drug resistance
  • 相关文献

参考文献3

二级参考文献26

  • 1金美娟,李秀红,邢旺兴.236株铜绿假单胞菌感染的临床分析[J].中华医院感染学杂志,2005,15(3):348-350. 被引量:45
  • 2钱小毛,赵仲农,王亚玲.绍兴地区铜绿假单胞菌亚胺培南耐药机制研究[J].中华医院感染学杂志,2005,15(7):815-818. 被引量:36
  • 3[2]NCCLS.Performance standards for antimicrobial disk susceptibility tests: Approved Standard[S].Eighth Edition,M2-A8.2003.23(1): 100.
  • 4[5]Jing JY,Po Rhsueh.β-Lactamases in clinical Pseudomonas isolates[J].Antimicrob Agents Chemother,2001,45(8): 2224-2228.
  • 5Langaee TY, Gagnon L, Huletsky A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob Agents Chemother, 2000, 44(3): 583-589.
  • 6Giakkoupi P, Petrikkos G, Tzouvelekis LS, et al. Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol, 2003, 41(2): 822-825.
  • 7Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother, 1998, 42(8): 2006-
  • 8Akasaka T, Tanaka M, Yamaguchi A, et al. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents
  • 9Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell, 1997, 88(6): 823-832.
  • 10Mouneimne H, Robert J, Jarlier V, et al. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1999, 43(1): 62-66.

共引文献152

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部